Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 6/20 | 0.35 |
| ▸ | XIAP | P98170 | 4/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9213719 | 0.81 | CXCR4 (0.49) | CXCR4ADRB1 | |
| SCHEMBL29811157 | 0.80 | OPRK1 (0.31) | — | |
| SCHEMBL9205301 | 0.79 | EGLN1 (0.40) | — | |
| SCHEMBL6100284 | 0.79 | BIRC2 (0.41) | BIRC2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1394889 | 0.77 | SLC6A9 (0.42) | — | |
| SCHEMBL8815561 | 0.76 | BIRC2 (0.40) | BIRC2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL21427272 | 0.75 | CXCR4 (0.55) | CXCR4ADRB1 | |
| SCHEMBL7871400 | 0.75 | ALDH1A1 (0.40) | — | |
| SCHEMBL7869921 | 0.74 | EGLN1 (0.39) | — | |
| SCHEMBL20624199 | 0.74 | EGLN1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293207-B2 | Radiometal-labeled amino acid analogs, imaging and therapeutic agents incorporating the same, and methods using the same | ZAVARZIN VALERY (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110070157-A1 | RADIOMETAL-LABELED AMINO ACID ANALOGS, IMAGING AND THERAPEUTIC AGENTS INCORPORATING THE SAME, AND METHODS USING THE SAME | ZAVARZIN VALERY | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070157-A1 | RADIOMETAL-LABELED AMINO ACID ANALOGS, IMAGING AND THERAPEUTIC AGENTS INCORPORATING THE SAME, AND METHODS USING THE SAME | SSTR5, SCTR, SSTR3 | BIRC2 2728/4885XIAP 2163/4885CXCR4 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.